Patients with CTCs expressing a cytokeratin epithelial marker and the CSC markers CD133 and/or CD44 had a higher risk of tumor recurrence and lower overall survival, compared to those with cytokeratin+/CD133−/CD44− CTCs. This evidence concerns the gene PROM1 and neoplasm.